All In Biotech

Drug Trial Radar · NCT06021860

A Phase IV, Two-part, Open-label Study Assessing the Pharmacokinetics, Safety and Pharmacodynamics of Spironolactone Oral Suspension in Pediatric Patients

A Phase IV, Two-part, Open-label Study Assessing the Pharmacokinetics, Safety and Pharmacodynamics of Single and Multiple Doses of Spironolactone Oral Suspension in Pediatric Patients With Edema Due to Heart Failure or Cirrhosis

Last checked: Nov 20, 2026Latest source record: Oct 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

96

Planned (sponsor's estimate)

Start

Jun 2027

Primary completion

Jun 2028

Study completion Dec 2028

Sponsor

Lead sponsor
CMP Development, LLCIndustry
Sponsor type
Industry
First posted
Sep 1, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a 2-part, 2 periods per part, open-label study with spironolactone oral suspension in pediatric patients with edema due to HF or hepatic cirrhosis. Both study parts will evaluate the safety, PK and PD of multiple doses of spironolactone in patients aged from birth to ≤17 years of age.

Conditions

  • Edema Due to Heart Failure or Cirrhosis

Interventions

  • Spironolactone Oral SuspensionDrug

    Spironolactone will be dosed on a mg/kg basis, with actual weight on Day 1 (pre-dose) determining the spironolactone suspension volume administered. Therefore, for a given patient, the dose administered on Day 1, based on the weight measured on Day 1, will be administered throughout their participation in the study. Spironolactone will be administered as a single dose in the single-dose periods (Group 4, Parts 1 and 2), and as QD dosing in the multiple-dose periods (Groups 1 to 4, Parts 1 and 2). The low and high doses to be administered during Part 2 of the study will be determined by the Safety Review Committee following their review of Part 1 data.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1: Absorption rate constant (Ka) of spironolactone (time^-1) in the multiple-dose periodTime frame: Pre-dose (Day 1) to 22-26 hours post-dose (Day 11)
  2. Part 2: Absorption rate constant (Ka) of spironolactone (time^-1) in the multiple-dose periodTime frame: Pre-dose (Day 1) to 22-26 hours post-dose (Day 11)
  3. Part 1: Total clearance from plasma after oral administration (CL/F) of spironolactone in the multiple-dose periodTime frame: Pre-dose (Day 1) to 22-26 hours post-dose (Day 11)
  4. Part 2: Total clearance from plasma after oral administration (CL/F) of spironolactone in the multiple-dose periodTime frame: Pre-dose (Day 1) to 22-26 hours post-dose (Day 11)
  5. Part 1: Volume of distribution after oral administration (V/F) of spironolactone in the multiple-dose periodTime frame: Pre-dose (Day 1) to 22-26 hours post-dose (Day 11)
  6. Part 2: Volume of distribution after oral administration (V/F) of spironolactone in the multiple-dose periodTime frame: Pre-dose (Day 1) to 22-26 hours post-dose (Day 11)
  7. Part 1: Total clearance from plasma after oral administration (CL/F) of canrenone in the multiple-dose periodTime frame: Pre-dose (Day 1) to 22-26 hours post-dose (Day 11)
  8. Part 2: Total clearance from plasma after oral administration (CL/F) of canrenone in the multiple-dose periodTime frame: Pre-dose (Day 1) to 22-26 hours post-dose (Day 11)
  9. Part 1: Volume of distribution after oral administration (V/F) of canrenone in the multiple-dose periodTime frame: Pre-dose (Day 1) to 22-26 hours post-dose (Day 11)
  10. Part 2: Volume of distribution after oral administration (V/F) of canrenone in the multiple-dose periodTime frame: Pre-dose (Day 1) to 22-26 hours post-dose (Day 11)
  11. Part 1: Change from baseline in body weight (kg) (Groups 1 through 3)Time frame: Day 1 to Day 18
  12. Part 1: Change from baseline in body weight (kg) (Group 4)Time frame: Day 1 to Day 26
  13. Part 2: Change from baseline in body weight (kg) (Groups 1 through 3)Time frame: Day 1 to Day 18
  14. Part 2: Change from baseline in body weight (kg) (Group 4)Time frame: Day 1 to Day 26
  15. Part 1: Change from baseline in sodium/potassium (Na/K) ratio (Groups 1 through 3)Time frame: Day -1 to Day 11
  16. Part 1: Change from baseline in sodium/potassium (Na/K) ratio (Group 4)Time frame: Day 8 to Day 19
  17. Part 2: Change from baseline in sodium/potassium (Na/K) ratio (Groups 1 through 3)Time frame: Day -1 to Day 11
  18. Part 2: Change from baseline in sodium/potassium (Na/K) ratio (Group 4)Time frame: Day 8 to Day 19
  19. Part 1: Change from baseline in fractional excretion of sodium (FENa; %) (Groups 1 through 3)Time frame: Day -1 to Day 11
  20. Part 1: Change from baseline in fractional excretion of sodium (FENa; %) (Group 4)Time frame: Day 8 to Day 19
  21. Part 2: Change from baseline in fractional excretion of sodium (FENa; %) (Groups 1 through 3)Time frame: Day -1 to Day 11
  22. Part 2: Change from baseline in fractional excretion of sodium (FENa; %) (Group 4)Time frame: Day 8 to Day 19

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.